These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23093903)

  • 1. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Pharm Res; 2012 Oct; 29(10):2845-59. PubMed ID: 22644590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
    Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
    Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
    Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary.
    Huang Z; Lin L; McGoverin C; Liu H; Wang L; Zhou QT; Lu M; Wu C
    Int J Pharm; 2018 Nov; 551(1-2):103-110. PubMed ID: 30217767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
    Pornputtapitak W; El-Gendy N; Berkland C
    J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
    Sun W; Ni R; Zhang X; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption.
    Sun W; Mao S; Shi Y; Li LC; Fang L
    J Pharm Sci; 2011 Aug; 100(8):3365-3373. PubMed ID: 21520089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dandelion inspired microparticles with highly efficient drug delivery to deep lung.
    Sun H; Yan S; Wu C; Ma J; Lu K; Cheng X; Yan W; Zhang S; Chen XD; Wu WD
    Colloids Surf B Biointerfaces; 2024 Dec; 244():114134. PubMed ID: 39121569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal efficacy of Itraconazole loaded PLGA-nanoparticles stabilized by vitamin-E TPGS: In vitro and ex vivo studies.
    Alhowyan AA; Altamimi MA; Kalam MA; Khan AA; Badran M; Binkhathlan Z; Alkholief M; Alshamsan A
    J Microbiol Methods; 2019 Jun; 161():87-95. PubMed ID: 30738109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
    Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
    Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
    Parikh T; Sandhu HK; Talele TT; Serajuddin AT
    Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying.
    Wan KY; Weng J; Wong SN; Kwok PCL; Chow SF; Chow AHL
    Eur J Pharm Biopharm; 2020 Apr; 149():238-247. PubMed ID: 32112895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of nanosuspensions into dry powders by spray drying: a case study.
    Chaubal MV; Popescu C
    Pharm Res; 2008 Oct; 25(10):2302-8. PubMed ID: 18509597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of stabilized itraconazole nanodispersions by using high-gravity technique.
    Zhang ZL; Le Y; Wang JX; Zhao H; Chen JF
    Drug Dev Ind Pharm; 2012 Dec; 38(12):1512-20. PubMed ID: 22435399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components studied by a mixture design.
    Foglio Bonda A; Rinaldi M; Segale L; Palugan L; Cerea M; Vecchio C; Pattarino F
    Eur J Pharm Sci; 2016 Feb; 83():175-83. PubMed ID: 26742430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryogenic liquids, nanoparticles, and microencapsulation.
    Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycol-poly(β-Benzyl-l-aspartate) (PEG-PBLA).
    Zong L; Li X; Wang H; Cao Y; Yin L; Li M; Wei Z; Chen D; Pu X; Han J
    Int J Pharm; 2017 Oct; 531(1):108-117. PubMed ID: 28830781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.